Immunohistochemical Techniques

Immunohistochemistry is a technique involving the use of antibody-antigen interactions to identify cellular and tissue components. One method can be accomplished by labeling an antibody known by an enzyme that produces a colored product after the reaction and then monitoring the sample to see if a reaction has occurred. In immunohistochemistry it is important to protect antigenic determinants (also known as epitopes) and binding sites to ensure accurate results.

Despite extensive methodological development, most of the techniques available for assessing hypoxia have drawbacks. The use of polarographic oxygen electrodes is limited to accessible tumor and immunohistochemical techniques to identify reduced nitroimidazoles such as pimonidazole, which require a biopsy. Because these two methods are invasive, development and validation of imaging-based noninvasive techniques are highly desired (4). Currently, positron emission tomography (PET) is the best verification imaging method for hypoxia imaging, but many magnetic resonance imaging (MRI) based techniques are also described (4, 40) (Table 3 ).

Breast cancer is increasingly recognized as a heterogeneous disease and advances in molecular technology and diagnostic methods have identified different subtypes. Subtype analysis relies primarily on immunohistochemical markers such as estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), but three histories are involved in gene expression profiling and next generation sequencing It is defined using Thing. New subtype within subtype. This new classification has both prognostic value and predictive value for treatment of early breast cancer as well as advanced breast cancer. In addition, genomic markers known to be sensitive and resistant have resulted in the approval of multiple targeted therapies while others are still under development. Finally, the discovery of immunological markers has paved the way for new immune functions.

Recently, our team at the University of Wisconsin Medical School and the Department of Public Health in Madison, Wisconsin extended the original study of Thompson et al. Using immunohistochemistry. The INMT protein itself was identified by several primate central nervous system tissues (Cozzi et al., 2011; Mavlyutov et al., 2012). Real-time coupling between the presence of INMT protein in brain tissue and the biosynthesis of DMT in these tissues remains a challenging research goal. For interested readers the scientific literature for the past 55 years on the presence of DMT and other tryptamine in human tissues and the scientific literature on "uid" recently were published by Steven Barker, Ethan McIlhenny and Rick Strassman (Barker et al.). Al. , 2012)